Skip to main content

Table 2 Mean change from baseline in additional effectiveness outcomes (effectiveness sample)

From: A 64-week, multicenter, open-label study of aripiprazole effectiveness in the management of patients with schizophrenia or schizoaffective disorder in a general psychiatric outpatient setting

Outcome

Mean ± SD

WHOQOL-BREF:

 

Baseline

71.0 ± 14.1

Change from baseline to week 12

2.2 ± 12.5*

Change from baseline to week 64

3.6 ± 12.0*

Change from baseline to endpoint (LOCF)

2.2 ± 11.3**

CGI-S:

 

Baseline

3.8 ± 1.1

Change from baseline to week 12

-0.6 ± 1.0***

Change from baseline to week 64

-0.7 ± 1.1***

Change from baseline to endpoint (LOCF)

-0.3 ± 1.1***

BPRS:

 

Baseline

49.8 ± 17.5

Change from baseline to week 12

-6.5 ± 10.5***

Change from baseline to week 64

-9.3 ± 11.6***

Change from baseline to endpoint (LOCF)

-5.8 ± 15.9***

  1. *P < 0.05 vs baseline; **P < 0.01 vs baseline; ***P < 0.001 vs baseline.
  2. BPRS = Brief Psychiatric Rating Scale; CGI-S = Clinical Global Impression scale Severity of Illness score; LOCF = last observation carried forward; WHOQOL-BREF = World Health Organization Quality of Life instrument, short version.